Specify a stock or a cryptocurrency in the search bar to get a summary
Iteos Therapeutics Inc
ITOSIteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Address: 321 Arsenal Street, Cambridge, MA, United States, 02472-5710
Analytics
WallStreet Target Price
37.4 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ITOS
Dividend Analytics ITOS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ITOS
Stock Valuation ITOS
Financials ITOS
Results | 2019 | Dynamics |